Kenton Lance Crowley

US Patent:

60179619, Jan 25, 2000

Filed:

Jul 8, 1999

Appl. No.:

9/350062

Inventors:

John Anthony Flores - Hemet CA
Kenton Lance Crowley - Temecula CA

International Classification:

A61K 31195
A61K 31135

US Classification:

514561

Abstract:

The present invention relates to a novel ointment combining Ketamine and n-butyl-p-aminobenzoate (BAB) that is self-administered topically by a subject to alleviate Neuropathic pain, Sympathetic Mediated pain, TMJ pain, SIJ pain and Osteoarthritic pain said subject is experiencing. The present invention is an improvement over the Ketamine only based ointment disclosed in U. S. Pat. No. 5,817,699.

US Patent:

58176993, Oct 6, 1998

Filed:

May 30, 1997

Appl. No.:

8/866770

Inventors:

John A. Flores - San Bernardino CA
Kenton L. Crowley - Temecula CA

International Classification:

A61K 31135

US Classification:

514647

Abstract:

The present invention relates to a process for producing a ketamine ointment that is self-administered topically by a subject to alleviate neuropathic, sympathetic medicated pain and myofacial pain said subject is experiencing. The present invention is also utilized to improve the motor skills, alertness, sleeping habits, energy level and overall well-being of a subject suffering from Parkinson's disease.

US Patent:

20180133272, May 17, 2018

Filed:

Nov 14, 2017

Appl. No.:

15/812770

Inventors:

- Incline Village NV, US
Kenton L. Crowley - Temecula CA, US

International Classification:

A61K 36/185
A61K 31/4045
A61K 31/05
A61K 31/352

Abstract:

A composition comprising cannabis extract and melatonin is provided, along with formulations for delivering the composition to a subject. The composition can include a base ingredient such as polyethylene glycol, gelatin, tapioca and/or pectin; natural sweeteners; and oils of peppermint, lavender, ginger, citrus, mango, etc. The formulation can include tablets, capsules, lozenges, troches, suppositories, tinctures, a transdermal patch, a vaporizer, a metered dose inhaler, etc. The formulation avoids harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids (both acidic and neutral forms), terpenes and flavonoids.

US Patent:

20170274030, Sep 28, 2017

Filed:

Apr 6, 2017

Appl. No.:

15/481394

Inventors:

- INCLINE VILLAGE NV, US
Kenton L. Crowley - Temecula CA, US

Assignee:

FARM TO FRAMA, INC. - INCLINE VILLAGE NV

International Classification:

A61K 36/185
A61K 31/352
A61K 31/05
A61K 36/534
A61K 45/06
A61K 9/00

Abstract:

A cannabinoid troche including polyethylene glycol (or other base ingredients such as gelatin and/or pectin) and oils of peppermint, ginger, citrus, mango, etc., that is administered buccally and/or sublingually. This dosage form demonstrates an improved efficacy with reduced side effects when compared to formulations of cannabinoids in capsules, oral solutions, tinctures, sprays and edibles. The troches avoid harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids, terpenes and flavonoids. The use of peppermint oil (and others) in the troche shows improved efficacy above and beyond that which is expected or seen without its use. The troches further allow for accurate and reproducible therapeutic effects with ease of dosage adjustments.